Jaime Modiano
Founder at ApopLogic Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Duke | M | - |
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | - |
| Donald Bellgrau | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| Paul Bunn | M | 79 |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| John M. Stewart | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| Daniel D. Chan | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| Lajos Gera | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| William N. Kelley | M | 84 |
University of Pennsylvania
| 35 years |
| Myles H. Tanenbaum | M | 93 |
University of Pennsylvania
| 35 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Vurgait | M | 59 |
University of Pennsylvania
| 1 years |
| William Coskey | M | 71 |
Texas A&M University
| 15 years |
| Scott Hoyt | M | - |
University of Pennsylvania
| 6 years |
| Lee Rash | M | - |
Texas A&M University
| 5 years |
| Helen Remeza | M | - |
University of Pennsylvania
| 5 years |
| Mindy B. Hegi | F | - |
Texas A&M University
| 5 years |
| John W. Glomb | M | - |
University of Pennsylvania
| 12 years |
| Jarrett Urban | M | - |
Texas A&M University
| 4 years |
| Roger Merritt | M | - |
University of Pennsylvania
| 3 years |
| Christopher Abundis | M | 46 |
Texas A&M University
| 5 years |
| Scott M. Gallin | M | 51 |
University of Pennsylvania
| 5 years |
| Brad Elliott Heidelberg | M | 48 |
Texas A&M University
| 4 years |
| Mark Teshoian | M | - |
Texas A&M University
| 5 years |
| Billy Macaulay | M | - |
Texas A&M University
| 5 years |
| Shiv Vikram Khemka | M | 61 |
University of Pennsylvania
| 2 years |
| Jim Weddle | M | 70 |
University of Pennsylvania
| 9 years |
| Brent Pilgrim | M | - |
Texas A&M University
| 6 years |
| Bryan Lemmerman | M | 49 |
Texas A&M University
| 5 years |
| Mark S. Kingsley | M | - |
University of Pennsylvania
| 7 years |
| Gary J. Brauchle | M | 50 |
Texas A&M University
| 5 years |
| Rich Ballew | M | - |
University of Pennsylvania
| 3 years |
| Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 years |
| Horacio Ferreira Rueda | M | 54 |
Texas A&M University
| 5 years |
| Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 years |
| Arcandra Tahar | M | 53 |
Texas A&M University
| 7 years |
| Richard Thomas | M | 43 |
Texas A&M University
| 4 years |
| Ben Carter | M | 43 |
Texas A&M University
| 5 years |
| Michael Colby | M | 42 |
Texas A&M University
| 5 years |
| Andy Jamison | M | - |
Texas A&M University
| 5 years |
| Miriam Provost | M | 63 |
University of Pennsylvania
| 4 years |
| Courtney Grobe | F | - |
Texas A&M University
| 5 years |
| Nick Losada | M | - |
Texas A&M University
| 6 years |
| Bob wilkinson | M | - |
Texas A&M University
| 5 years |
| Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 years |
| Dusty Culbertson | M | - |
Texas A&M University
| 5 years |
| Leif-Olof Fager | M | - |
University of Pennsylvania
| 8 years |
| Mehul Trivedi | M | 53 |
University of Pennsylvania
| 9 years |
| Yong Li | M | 55 |
University of Pennsylvania
| 4 years |
| Julio E. Vega | M | - |
University of Pennsylvania
| 7 years |
| Joel Kallett | M | - |
University of Pennsylvania
| 5 years |
| Lisa Granick | F | - |
University of Pennsylvania
| 2 years |
| Lance J. Graber | M | 62 |
University of Pennsylvania
| 8 years |
| Philip Rolchigo | M | 62 |
University of Pennsylvania
| 5 years |
| Charles Hebard | M | - |
University of Pennsylvania
| 11 years |
| Renée S. Grossman | F | 56 |
University of Pennsylvania
| 7 years |
| Matthew P. Kerin | M | 43 |
Texas A&M University
| 5 years |
| Vincent J. Lambert | M | - |
University of Pennsylvania
| 4 years |
| Tim Sledge | M | - |
University of Pennsylvania
| 4 years |
| Pat J. Sheridan | M | - |
University of Pennsylvania
| 2 years |
| Stephen Waxman | M | - |
University of Pennsylvania
| 4 years |
| Timothy Mauro | M | - |
University of Pennsylvania
| 4 years |
| Joe Weinlick | M | - |
University of Pennsylvania
| 4 years |
| Stephen E. Sellick | M | - |
University of Pennsylvania
| 4 years |
| Mark E. Koznarek | M | - |
University of Pennsylvania
| 2 years |
| Thomas J. Fontaine | M | 58 |
University of Pennsylvania
| 3 years |
| Vishal Saluja | M | 57 |
University of Pennsylvania
| 4 years |
| Seth J. Gerson | M | - |
University of Pennsylvania
| 3 years |
| Pano Karambelas | M | - |
University of Pennsylvania
| 5 years |
| Don San Jose | M | - |
University of Pennsylvania
| 4 years |
| Justin T. Hott | M | - |
University of Pennsylvania
| 3 years |
| Dan Chamby | M | - |
University of Pennsylvania
| 2 years |
| Linda Ba | F | - |
University of Pennsylvania
| 4 years |
| Peter Blumen | M | 63 |
University of Pennsylvania
| 2 years |
| Doug Melancon | M | - |
University of Pennsylvania
| 4 years |
| Justin C. Heyman | M | - |
University of Pennsylvania
| 4 years |
| Nick Lobaccaro | M | - |
University of Pennsylvania
| 4 years |
| Edward A. Johnson | M | - |
University of Pennsylvania
| 2 years |
| Henry O'Connor | M | - |
University of Pennsylvania
| 3 years |
| Jason A. Hammerman | M | - |
University of Pennsylvania
| 4 years |
| Richard J. Malnight | M | - |
University of Pennsylvania
| 3 years |
| Stephen H. Dover | M | 63 |
University of Pennsylvania
| 1 years |
| Richard Solit | M | - |
University of Pennsylvania
| 4 years |
| Guy Andrew Judkowski | M | - |
University of Pennsylvania
| 4 years |
| Thomas M. Brunts | M | - |
University of Pennsylvania
| 2 years |
| Jacqueline Lesage-Krause | F | - |
University of Pennsylvania
| 4 years |
| Kyle McClements | M | - |
University of Pennsylvania
| 4 years |
| Ralph Sutton | M | - |
University of Pennsylvania
| 4 years |
| Jason Colodne | M | 52 |
University of Pennsylvania
| 4 years |
| Thomas D. Aarts | M | - |
University of Pennsylvania
| 2 years |
| Patrick Joseph Moriarty | M | - |
University of Pennsylvania
| 4 years |
| Jeff Bernardo | M | 54 |
University of Pennsylvania
| 4 years |
| John R. Sinnenberg | M | - |
University of Pennsylvania
| 2 years |
| John Staszak | M | - |
University of Pennsylvania
| 4 years |
| Andrew W. Jeffrey | M | - |
University of Pennsylvania
| 4 years |
| Christina Boni | F | - |
University of Pennsylvania
| 4 years |
| Tom Baxter | M | - |
University of Pennsylvania
| 4 years |
| Aaron Cowen | M | - |
University of Pennsylvania
| 4 years |
| Andrew Cueva | M | 53 |
University of Pennsylvania
| 4 years |
| Lyle Berkowitz | M | - |
University of Pennsylvania
| 4 years |
| Jonathan Perera | M | - |
University of Pennsylvania
| 1 years |
| Lester A. Zuckerman | M | - |
University of Pennsylvania
| 6 years |
| Ryan Newman | M | - |
University of Pennsylvania
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jaime Modiano
- Personal Network
